Trial Profile
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Idecabtagene vicleucel (Primary) ; Bortezomib; Bortezomib; Carfilzomib; Daratumumab; Dexamethasone; Dexamethasone; Elotuzumab; Ixazomib; Lenalidomide; Pomalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms KarMMa-3
- Sponsors Celgene Corporation
- 04 Apr 2024 According to a Bristol-Myers Squibb media release, company announced that U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy based on results from the KarMMa-3 trial.
- 21 Mar 2024 According to a Bristol-Myers Squibb media release, the company announced that the European Commission (EC) has granted approval to Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
- 15 Mar 2024 According to a Bristol-Myers Squibb and a 2seventy bio media release, Abecma was recently approved in Japan and Switzerland and also received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the extension of indication for patients with relapsed and/or refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.